Novavax Statistics

Total Valuation

Novavax has a market cap or net worth of MXN 29.09 billion. The enterprise value is 21.92 billion.

Market Cap	29.09B
Enterprise Value	21.92B

Important Dates

The last earnings date was Friday, August 8, 2025.

Earnings Date	Aug 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	162.42M
Shares Outstanding	n/a
Shares Change (YoY)	+30.54%
Shares Change (QoQ)	-0.23%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	136.72M

Valuation Ratios

The trailing PE ratio is 3.65.

PE Ratio	3.65
Forward PE	n/a
PS Ratio	1.43
PB Ratio	41.00
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 2.88, with an EV/FCF ratio of -1.83.

EV / Earnings	2.75
EV / Sales	1.09
EV / EBITDA	2.88
EV / EBIT	3.20
EV / FCF	-1.83

Financial Position

The company has a current ratio of 2.36, with a Debt / Equity ratio of 6.07.

Current Ratio	2.36
Quick Ratio	2.16
Debt / Equity	6.07
Debt / EBITDA	0.56
Debt / FCF	-0.36
Interest Coverage	15.55

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	14.52%
Return on Invested Capital (ROIC)	467.59%
Return on Capital Employed (ROCE)	38.67%
Revenue Per Employee	21.37M
Profits Per Employee	8.38M
Employee Count	952
Asset Turnover	0.68
Inventory Turnover	47.58

Taxes

In the past 12 months, Novavax has paid 161.48 million in taxes.

Income Tax	161.48M
Effective Tax Rate	1.98%

Stock Price Statistics

The stock price has decreased by -21.93% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-21.93%
50-Day Moving Average	134.63
200-Day Moving Average	153.11
Relative Strength Index (RSI)	73.86
Average Volume (20 Days)	1,870

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.38

Income Statement

In the last 12 months, Novavax had revenue of MXN 20.34 billion and earned 7.97 billion in profits. Earnings per share was 47.99.

Revenue	20.34B
Gross Profit	11.63B
Operating Income	6.91B
Pretax Income	8.14B
Net Income	7.97B
EBITDA	7.68B
EBIT	6.91B
Earnings Per Share (EPS)	47.99

Full Income Statement

Balance Sheet

The company has 11.55 billion in cash and 4.31 billion in debt, giving a net cash position of 7.24 billion.

Cash & Cash Equivalents	11.55B
Total Debt	4.31B
Net Cash	7.24B
Net Cash Per Share	n/a
Equity (Book Value)	709.54M
Book Value Per Share	4.38
Working Capital	10.00B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -11.90 billion and capital expenditures -89.97 million, giving a free cash flow of -11.99 billion.

Operating Cash Flow	-11.90B
Capital Expenditures	-89.97M
Free Cash Flow	-11.99B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 57.18%, with operating and profit margins of 33.96% and 39.20%.

Gross Margin	57.18%
Operating Margin	33.96%
Pretax Margin	39.99%
Profit Margin	39.20%
EBITDA Margin	37.78%
EBIT Margin	33.96%
FCF Margin	n/a

Dividends & Yields

Novavax does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-30.54%
Shareholder Yield	n/a
Earnings Yield	27.41%
FCF Yield	-41.21%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Novavax has an Altman Z-Score of -1.72 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.72
Piotroski F-Score	5